- Report
- April 2026
- 122 Pages
Global
From €3500EUR$4,013USD£3,026GBP
- Report
- April 2026
- 112 Pages
Global
From €3500EUR$4,013USD£3,026GBP
- Report
- September 2026
- 128 Pages
Global
From €3500EUR$4,013USD£3,026GBP
- Report
- September 2026
- 139 Pages
Global
From €3500EUR$4,013USD£3,026GBP
- Report
- September 2026
- 127 Pages
Global
From €3500EUR$4,013USD£3,026GBP
- Report
- August 2026
- 121 Pages
Global
From €3500EUR$4,013USD£3,026GBP
- Report
- March 2026
- 150 Pages
Global
From €4532EUR$4,850USD£3,786GBP
- Report
- February 2026
- 170 Pages
Global
From €4532EUR$4,850USD£3,786GBP
- Report
- February 2026
- 186 Pages
Global
From €4532EUR$4,850USD£3,786GBP
- Report
- November 2025
- 150 Pages
Global
From €4532EUR$4,850USD£3,786GBP
- Clinical Trials
- August 2026
- 1100 Pages
Global
From €3224EUR$3,450USD£2,693GBP
- Report
- August 2026
- 53 Pages
Global
From €7008EUR$7,500USD£5,854GBP
- Report
- February 2026
- 200 Pages
United States
From €2794EUR$2,990USD£2,334GBP
- Report
- February 2026
- 200 Pages
Europe
From €2794EUR$2,990USD£2,334GBP
- Report
- April 2026
- 148 Pages
North America
From €3737EUR$3,999USD£3,122GBP
- Report
- August 2026
- 120 Pages
United States
From €3691EUR$3,950USD£3,083GBP
- Report
- August 2026
- 60 Pages
United States
From €4625EUR$4,950USD£3,864GBP
- Report
- February 2026
- 100 Pages
United States
From €3691EUR$3,950USD£3,083GBP
- Report
- May 2026
- 110 Pages
United States
From €4438EUR$4,750USD£3,708GBP
- Report
- March 2026
- 250 Pages
United States
From €4532EUR$4,850USD£3,786GBP

Macular Degeneration is a condition that affects the central part of the retina, known as the macula, which is responsible for sharp, central vision. It is the leading cause of vision loss in people over the age of 50. Optical treatments for Macular Degeneration include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to reduce the risk of further vision loss by sealing off leaking blood vessels in the macula. Photodynamic therapy is used to reduce the growth of abnormal blood vessels in the macula. Anti-VEGF injections are used to reduce the growth of abnormal blood vessels and improve vision.
Companies in the Macular Degeneration market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more